ETF Holdings Breakdown of LGND

LGND institutional holdings

The adjusted close for LGND on 2025-11-12 was 205.61

The following institutional investment holdings of LGND have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	13,135	USD 2,700,687 -1.5%	205.61
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	2,303 -0.3%	USD 473,520 -1.8%	205.61
2025-11-12	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	23,374	USD 4,805,928	205.61
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	12,794	USD 2,630,574	205.61
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	12,794 0.3%	USD 2,630,574 -1.2%	205.61
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	137	USD 28,169 -1.5%	205.61
Total =		64,537	USD 13,269,452

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with LGND

Ligand Pharmaceuticals (NASDAQ:LGND) Given New $190.00 Price Target at Oppenheimer

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) had its price objective upped by Oppenheimer from $167.00 to $190.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s target price points to a potential upside of 13.27% from the stock’s current price. A number of […] - 2025-09-05 05:03:20

Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High After Analyst Upgrade

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $167.00 to $190.00. Oppenheimer currently has an outperform rating on the stock. Ligand Pharmaceuticals traded as high as $166.99 and last traded at $166.54, with […] - 2025-09-04 02:18:55

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $157.00 Consensus Price Target from Brokerages

Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last […] - 2025-08-27 02:07:03

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Position Lowered by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System decreased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,519 shares of the biotechnology company’s stock after selling 844 shares during the period. Maryland State […] - 2025-08-15 04:50:59

Mutual of America Capital Management LLC Reduces Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Mutual of America Capital Management LLC lowered its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.8% in the first quarter, HoldingsChannel.com reports. The fund owned 2,752 shares of the biotechnology company’s stock after selling 110 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Ligand Pharmaceuticals were […] - 2025-08-13 06:48:50

Deutsche Bank AG Sells 1,087 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Deutsche Bank AG decreased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 0.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 287,965 shares of the biotechnology company’s stock after selling 1,087 shares during the quarter. Deutsche Bank AG owned 1.49% […] - 2025-08-13 05:19:03

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a hold rating to a buy rating in a report published on Saturday. Several other analysts have also weighed in on LGND. Royal Bank Of Canada raised their price objective on Ligand Pharmaceuticals from $155.00 to $185.00 and gave the company an […] - 2025-08-12 04:12:53

Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes

(RTTNews) - Ligand Pharmaceuticals Incorporated (LGND) Monday said it intends to privately offer $400 million of senior notes due 2030. - 2025-08-11 08:37:20

LGND Crosses Above Average Analyst Target

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $144.75, changing hands for $146.32/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-08-08 08:32:29

Insiders Buy the Holdings of TECB ETF

A look at the weighted underlying holdings of the iShares U.S. Tech Breakthrough Multisector ETF (TECB) shows an impressive 14.6% of holdings on a weighted basis have experienced insider buying within the past six months. Ligand Pharmaceuticals Inc (Symbol: LGND), which makes - 2025-07-29 10:45:36

Victory Capital Management Inc. Purchases 13,456 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Victory Capital Management Inc. lifted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 94.6% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 27,678 shares of the biotechnology company’s stock after acquiring an additional 13,456 shares during the period. Victory Capital Management Inc.’s holdings in Ligand Pharmaceuticals were worth $2,910,000 […] - 2025-07-29 04:23:02

Mutual of America Capital Management LLC Cuts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Mutual of America Capital Management LLC cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.8% during the first quarter, HoldingsChannel.com reports. The fund owned 2,752 shares of the biotechnology company’s stock after selling 110 shares during the period. Mutual of America Capital Management LLC’s holdings in Ligand Pharmaceuticals were […] - 2025-07-24 04:37:00

Arizona State Retirement System Acquires 110 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Arizona State Retirement System raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,407 shares of the biotechnology company’s stock after acquiring an additional 110 shares during the […] - 2025-07-22 07:06:52

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director John W. Kozarich sold 934 shares of Ligand Pharmaceuticals stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $125.00, for a total value of $116,750.00. Following the transaction, the director owned 46,456 shares of the company’s stock, valued […] - 2025-07-14 05:38:47

Oregon Public Employees Retirement Fund Cuts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Oregon Public Employees Retirement Fund trimmed its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 4,342 shares of the biotechnology company’s stock after selling 100 shares during the quarter. Oregon Public Employees Retirement […] - 2025-07-09 05:43:24

Allspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Allspring Global Investments Holdings LLC decreased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,419 shares of the biotechnology company’s stock after selling 3,643 shares during the quarter. Allspring Global […] - 2025-07-04 05:06:54

Illinois Municipal Retirement Fund Increases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Illinois Municipal Retirement Fund increased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 9.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,725 shares of the biotechnology company’s stock after purchasing an additional 902 […] - 2025-07-02 05:28:54

State of Alaska Department of Revenue Sells 269 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

State of Alaska Department of Revenue decreased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.5% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 10,470 shares of the biotechnology company’s stock after selling 269 shares during the quarter. State of Alaska Department of Revenue’s holdings in Ligand Pharmaceuticals were worth […] - 2025-06-26 04:44:48

Opal Wealth Advisors LLC Purchases Shares of 305 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Opal Wealth Advisors LLC purchased a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 305 shares of the biotechnology company’s stock, valued at approximately $32,000. A number of other hedge funds have […] - 2025-06-17 04:58:58

Handelsbanken Fonder AB Has $700,000 Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Handelsbanken Fonder AB raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,658 shares of the biotechnology company’s stock after buying an additional 800 shares during […] - 2025-06-16 05:01:01

Rhumbline Advisers Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Rhumbline Advisers cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 57,456 shares of the biotechnology company’s stock after selling 1,989 shares during the period. Rhumbline Advisers’ holdings in Ligand Pharmaceuticals […] - 2025-06-13 04:36:56

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Average Price Target from Analysts

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have updated their coverage on the stock […] - 2025-06-13 02:32:49

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 10,563 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 26.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 50,401 shares of the biotechnology company’s stock after […] - 2025-06-03 05:13:09

Squarepoint Ops LLC Acquires Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Squarepoint Ops LLC acquired a new stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the fourth quarter, HoldingsChannel reports. The fund acquired 16,799 shares of the biotechnology company’s stock, valued at approximately $1,800,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management […] - 2025-05-30 06:09:00

Bank of America Corp DE Has $11.51 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Bank of America Corp DE lifted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 107,439 shares of the biotechnology company’s stock after buying an additional 2,533 shares during the quarter. Bank of America Corp DE’s holdings in Ligand Pharmaceuticals […] - 2025-05-23 04:36:48

Jane Street Group LLC Sells 1,083 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Jane Street Group LLC reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,369 shares of the biotechnology company’s stock after selling 1,083 shares during the quarter. Jane Street Group LLC’s […] - 2025-05-20 04:30:46

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Consensus Target Price from Analysts

Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock […] - 2025-05-19 02:14:54

The Manufacturers Life Insurance Company Increases Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

The Manufacturers Life Insurance Company increased its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 9.1% during the 4th quarter, Holdings Channel reports. The firm owned 9,373 shares of the biotechnology company’s stock after acquiring an additional 779 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Ligand Pharmaceuticals were worth […] - 2025-05-14 05:10:50

Ligand Pharmaceuticals (NASDAQ:LGND) Cut to “Sell” at StockNews.com

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday. Several other brokerages also recently commented on LGND. Oppenheimer raised their price objective on Ligand Pharmaceuticals from $142.00 to $145.00 and gave the stock an “outperform” […] - 2025-05-14 03:10:53

Price T Rowe Associates Inc. MD Raises Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Price T Rowe Associates Inc. MD grew its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,518 shares of the biotechnology company’s stock after buying an additional 1,781 […] - 2025-05-09 05:47:11

Back to Listing

Disclaimer